Authors

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

Matthew Sample

Understanding the FDA's Exemption for DSCSA Compliance

a year ago

In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.

Authors

Multi-Indication Drug Branding in Today’s Pharmaceutical Industry

Understanding the FDA's Exemption for DSCSA Compliance

Trending on Pharmaceutical Commerce

From Data Overload to Intelligent Commercialization: How Pharma Can Turn Connection Into Competitive Advantage

Pharma Pulse: Long COVID's Enduring Challenge Amid Major US Manufacturing Surge

Is Faster FDA Review Enough to Justify Onshoring?

Novartis Unveils Expansive North Carolina Manufacturing Hub to Strengthen US Drug Supply Chain